Galera Therapeutics

What Galera Therapeutics does

Galera Therapeutics was a clinical-stage biopharmaceutical company developing small-molecule therapeutics designed to address oxidative stress and related biological pathways in cancer treatment and supportive care. The company's core technology platforms consisted of proprietary superoxide dismutase (SOD) mimetics (avasopasem and rucosopasem) intended to reduce radiotherapy- and chemotherapy-induced toxicities, and nitric oxide synthase (NOS) inhibitors (tilarginine) acquired via Nova Pharmaceuticals for use in oncology and critical care indications.

The company's business model was that of a pre-revenue clinical-stage biotech with no FDA-approved products and no recurring product revenue from 2021 through 2025. Revenue, where any existed, derived from milestone payments or licensing arrangements rather than commercial sales, and value was realized primarily through eventual product commercialization, partnership monetization, or asset divestiture. The company had secured FDA Fast Track and RMAT designations for avasopasem but received a Complete Response Letter in 2023 for the radiotherapy-induced severe oral mucositis indication, triggering a 70% workforce reduction and a fundamental pivot.

Galera underwent a multi-stage corporate transformation through 2024–2026: the December 2024 acquisition of Nova Pharmaceuticals added the NOS inhibitor program; the October 2025 sale of the dismutase mimetics portfolio to Biossil for up to $105 million monetized the legacy SOD platform; and the April 2026 announcement followed by August 2026 completion of a reverse merger with Obsidian Therapeutics, concurrent with a $350 million private placement, left legacy Galera shareholders holding approximately 1.8% of the combined entity. Following the merger, Galera's independent corporate existence effectively ended, and its remaining assets became part of the Obsidian-led enterprise.

Name

Galera Therapeutics

Legal name

Galera Therapeutics, Inc.

Website

https://galeratx.com

Company type

Private

Founded year

2012

Operating status

Acquired

Headcount range

11–50 employees

Short description

Galera Therapeutics was a clinical-stage biopharmaceutical company developing small-molecule SOD mimetics and NOS inhibitors for cancer-related indications; pre-revenue with no approved products, it executed asset sales to Biossil and ultimately merged into Obsidian Therapeutics in 2026.

Ownership category

akta.pro rank

Product category

Oncology Biopharmaceuticals (Radioprotection and Radiosensitization)

NAICS

Scientific Research and Development Services (5417)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Gastrointestinal Oncology (HLAKAFAK)

Keywords

• Clinical-stage biopharmaceutical
• Oncology therapeutics
• Disruptive superoxide therapeutics
• Radiotherapy protectants
• Small molecule drug development

Headquarters

HQ city

Malvern

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Pharmaceutical Product Sales: Pre-revenue biotech company. If investigational therapies receive FDA approval, the company plans to commercialize products and generate revenue through pharmaceutical sales.
2. Asset Divestiture/Milestone Payments: Galera sold its dismutase mimetics portfolio to Biossil for up to $105 million, receiving upfront payments and potential future milestone payments. Also receives contingent value rights from merger with Obsidian.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Galera Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of small-molecule superoxide dismutase mimetics for oncology. Its lead candidates — avasopasem manganese (radioprotection for severe oral mucositis in head-and-neck cancer), rucosopasem manganese (radiotherapy/chemotherapy-induced lung injury), and tilarginine (tumor radiosensitizer for pancreatic cancer) — are intended to be administered alongside standard radiotherapy and chemotherapy regimens.

Product overview

Galera Therapeutics is a clinical-stage biopharmaceutical company developing a portfolio of proprietary small molecule drug candidates targeting critical vulnerabilities in cancer cells, immune cells, and the tumor microenvironment. The company's pipeline consists of two distinct therapeutic approaches: superoxide dismutase (SOD) mimetics (avasopasem and rucosopasem) for reducing radiotherapy-induced toxicity and enhancing cancer treatment, and nitric oxide synthase (NOS) inhibitors (tilarginine) for treating resistant breast cancers including metaplastic and triple-negative subtypes. These are investigational therapies in various stages of clinical development.

Differentiator

Problem solved

Functional benefit

Products and services

• Avasopasem manganese A manganese-based small-molecule superoxide dismutase mimetic administered intravenously alongside radiotherapy to selectively protect normal oral mucosa from radiation-induced damage in patients receiving cisplatin-based chemoradiotherapy for locally advanced head-and-neck cancer.
• Rucosopasem manganese A manganese-based superoxide dismutase mimetic in clinical development for the prevention of radiation- and chemotherapy-induced lung injury (pneumonitis) in patients receiving treatment for lung cancer and other thoracic tumors.
• Tilarginine A nitric oxide synthase inhibitor in early-stage development intended to be combined with radiotherapy as a tumor-selective radiosensitizer for patients with locally advanced pancreatic cancer and other solid tumors.

Quantifiable outcome

• One-year reductions in cisplatin-related chronic kidney disease (CKD) in head and neck cancer patients treated with avasopasem manganese from Phase 3 ROMAN trial
• +1 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered major and minor.

• BiossilmajorStrategic or Co-development Partner · 23 October 2025Toronto-based company acquired Galera's dismutase mimetics portfolio including avasopasem and rucosopasem for up to $105 million. Biossil assumes development and commercialization obligations including royalties. Galera retains interest through milestone payments.
• Nova PharmaceuticalsmajorStrategic or Co-development Partner · 31 December 2024Galera completed acquisition of Nova Pharmaceuticals, a biotechnology company developing pan-NOS inhibitors for treating resistant breast cancers including metaplastic breast cancer and triple-negative breast cancer. Deal involved issuing shares and warrants with investor funding support.
• Houston Methodist Research Institute (HMRI)minorStrategic or Co-development PartnerClinical trial partner mentioned in pipeline for breast cancer trials.
• National Cancer Institute (NCI)minorStrategic or Co-development PartnerFederal cancer research institute partnering on clinical trials.
• I-SPY 2 Trial NetworkminorStrategic or Co-development PartnerInvestigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis 2 - adaptive clinical trial platform for breast cancer.

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• ImmunoGen (AbbVie): Oncology-focused biotech acquired by AbbVie in 2024 for $10.1B, specializing in ADCs for cancer. Comparable as a larger oncology specialty pharma developing novel mechanism-based therapies for solid tumors, including breast cancer indications like TNBC that overlap with Galera's tilarginine program.

Direct peers

• Rigel Pharmaceuticals: Commercial-stage hematology and oncology specialty pharmaceutical company. Comparable as a small-to-mid-cap specialty pharma developing therapeutics for hematologic and oncologic indications using proprietary small molecule approaches.
• Syndax Pharmaceuticals: Clinical-stage oncology company developing therapies for treatment-resistant cancers including breast cancer. Comparable as a small-cap oncology biotech targeting resistant cancer populations with proprietary small molecule mechanisms.
• Spectrum Pharmaceuticals: Specialty pharmaceutical company developing and commercializing oncology and hematology therapeutics. Comparable as a clinical/commercial-stage oncology specialty pharma with similar product profile targeting niche cancer indications.
• Monopar Therapeutics: Clinical-stage oncology biotech developing proprietary therapeutics for cancer treatment, including radiopharmaceuticals. Closely comparable to Galera as a small-cap, clinical-stage oncology company targeting underserved cancer indications with proprietary technology.
• Aprea Therapeutics: Clinical-stage oncology biotech developing therapeutics targeting the p53 pathway in cancer. Comparable as a small-cap, clinical-stage oncology company focused on novel mechanisms for resistant cancers, with similar reverse-merger/strategic alternatives history.
• Mersana Therapeutics: Clinical-stage oncology company developing antibody-drug conjugates (ADCs) for cancer treatment. Galera board member Lawrence Alleva also serves on Mersana's board. Comparable as a small-cap clinical-stage oncology biotech with similar development-stage dynamics.
• Corcept Therapeutics: Commercial-stage specialty pharmaceutical company focused on oncology and metabolic diseases, marketing cortisol modulators. Comparable to Galera as a specialty pharma company developing mechanism-based therapies in oncology with similar business model.
• Obsidian Therapeutics: Clinical-stage cell therapy company that completed an August 2026 reverse merger with Galera, with the combined entity operating under the Obsidian name. Directly comparable as a small public clinical-stage oncology developer with similar financing dynamics and pre-revenue biotech structure.
• Checkpoint Therapeutics: Clinical-stage immuno-oncology company developing targeted therapies for solid tumors. Comparable as a small-cap, clinical-stage oncology company with similar pre-revenue biotech structure and clinical execution risk profile.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xtwitter.com/GaleraTx
• LinkedInlinkedin.com/company/galera-therapeutics-inc-

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds10 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Galera Therapeutics